A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 62
- Population
- ALL · 65 Years to 90 Years
- Duration
- 2016-11-01 to 2022-09-01
- Intervention
- Longeveron Mesenchymal Stem Cells (LMSCs); Fluzone High Dose Vaccine
- Comparator
- Not reported
- Outcomes measured
- The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untowar…; The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglut…; Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels: — Baseline, month 6 a…; Differences in rate of decline from Aging Frailty — Baseline, month 6 and month 12 after infusion; Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment — Baseline, month 6 and…; PROMIS Short Form 20a questionnaire — Baseline, month 6 and month 12 after infusion; PROMIS Mobility questionnaire — Baseline, month 6 and month 12 after infusion; PROMIS Upper Extremity questionnaire — Baseline, month 6 and month 12 after infusion; Short Form 36 questionnaire — Baseline, month 6 and month 12 after infusion; IIEF questionnaire — Baseline, month 6 and month 12 after infusion; SQOL-F questionnaire — Baseline, month 6 and month 12 after infusion; Death from any cause — Within 12 months after infusion; Falls Efficacy Scale-International (FES-I) — Baseline, month 6 and month 12 after infusion; Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels: — Baseline, month 6 and mo…; Rate of decline in Aging Frailty status as assessed by the 6 minute walk test — Baseline, month 6 and month 12 after in…; Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB) — Baseline, month…; Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test — Baseline, month 6 and month 12 after inf…; Rate of decline in Aging Frailty status as assessed by the Weight Loss — Baseline, month 6 and month 12 after infusion; Rate of decline in Aging Frailty status as assessed by the Handgrip Test — Baseline, month 6 and month 12 after infusion
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Frailty · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.